Skip to main content

Table 4 The sensitivity analysis at 45% sharing rate for marginal annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Variables Annual cost of operation Sharing rate # of HIV averted # of HCV averted HIV cost saved HCV cost saved Cost-effectiveness ratio HCV Cost-effectiveness ratio HIV Cost-benefit ratio HCV Cost-benefit ratio HIV
Post SIF $2,182,800 45% 19 115 $1,817,745 $1,858,645 $18,980 $114,884 1.85 1.8
Two SIF $2,182,800 35% 16 99 $1,186,080 $1,296,357 $22,048 $136,425 1.6 1.5
Three SIF $2,182,800 27% 7 43 -$708,915 -$671,651 $50,763 $311,829 0.7 0.68
Four SIF $2,182,800 23% 7 43 -$708,915 -$671,651 $50,763 $311,829 0.7 0.68
Five SIF $2,182,800 20% 7 43 -$708,915 -$671,651 $50,763 $311,829 0.7 0.68
Six SIF $2,182,800 16.00% 7 43 -$708,915 -$671,651 $50,763 $311,829 0.7 0.68
Seven SIF $2,182,800 12% 7 43 -$708,915 -$671,651 $50,763 $311,829 0.7 0.68
Average $2,182,800 9% 10 61 -$540,750 -$203,253 $42,120 $258,636 1 0.95